Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögrens syndrome
Arthritis & Rheumatism, 11/06/09
Pijpe J et al. – Sequential parotid biopsy specimens obtained from patients with primary SS before and after rituximab treatment demonstrated histopathologic evidence of reduced glandular inflammation and redifferentiation of lymphoepithelial duct lesions to regular striated ducts as a putative morphologic correlate of increased parotid flow and normalization of the salivary sodium content. These histopathologic findings in a few patients underline the efficacy of B cell depletion and indicate the potential for glandular restoration in SS
Methods- Phase II study
- Incisional parotid biopsy specimen obtained from 5 patients with primary SS before and 12 weeks after rituximab treatment (4 infusions of 375 mg/m2)
- Relative amount of parotid parenchyma, lymphocytic infiltrate, and fat, and the presence/quantity of germinal centers and lymphoepithelial duct lesions evaluated
- Immunohistochemical characterization performed to analyze the B:T cell ratio of lymphocytic infiltrate (CD20, CD79a, CD3) and cellular proliferation in acinar parenchyma (by double immunohistologic labeling for cytokeratin 14 and Ki-67)
- Histologic data assessed for correlations with parotid flow rate and saliva composition
- 4 patients showed increased salivary flow rate and normalization of initially increased salivary sodium concentration
- Following rituximab treatment, lymphocytic infiltrate reduced, with decreased B:T cell ratio and (partial) disappearance of germinal centers
- Amount and extent of lymphoepithelial lesions decreased in 3 patients and completely absent in 2 patients
- Initially increased proliferation of acinar parenchyma in response to inflammation reduced in all patients
Today in Autoimmune/Heritable...keeping you current
Receive free subspecialty "5-minute updates" via email
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
Rheumatology, 10/23/09
Lung involvement in patients with primary Sjögrens syndrome: What are the predictors?
Rheumatology International, 10/26/09
Vaccination, atherosclerosis and systemic lupus erythematosus
Lupus, 11/05/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Sponsor
Article Search
Sponsor


See Latest Articles


